Pharma & Bio
- Hanmi Licenses Muscle-Preserving Obesity Candidate to Genentech for Up to $2.3 Billion
Hanmi Pharmaceutical licensed obesity drug candidate HM17321 to Roche's Genentech for up to $2.3 billion, including a $190 million upfront payment.
- OliX Grants Hansoh Pharma Exclusive Rights to Two siRNA Sequences, With Room for More
OliX Pharmaceuticals has licensed development and commercialization rights to two siRNA sequences to China's Hansoh Pharma, with same-target follow-ons possible
- Korea's Second-Quarter Earnings Show a Broad but Uneven Profit Recovery
Q2 results from Dongbu E&C, HiteJinro, HLB Pharma and Stonebridge Ventures point to a profit recovery spreading across Korea's mid-cap economy.
- Korean Pharma Earnings Diverge: JW Surges 33% as Huons and Medytox Profits Slide
Second-quarter results split Korea's mid-cap drugmakers: JW Pharmaceutical's profit jumped 32.7% while Huons fell 77.6%, Medytox slipped and Lunit's revenue gre
- Daewoo E&C Nearly Triples Second-Quarter Profit as Samyang Packaging Grinds Higher
Daewoo E&C's Q2 operating profit jumped 182.6% to 232.3 billion won and Samyang Packaging added 21.4%, an early read on Korea's second-quarter earnings.
- Korea Drills Its Drugmakers on Global GMP as Export Ambitions Grow
Back-to-back Seoul seminars on data integrity, continuous manufacturing and PAT show Korea's drug regulator funding GMP training for export-bound pharma firms.
- Hanmi's Q2 Operating Profit More Than Doubles on 29% Sales Jump
Hanmi Pharm posted Q2 revenue of 467.2 billion won and operating profit of 131 billion won, with margins widening to 28% from about 17% a year earlier.
- Korean Drug Developers Turn to Partnering at Bio USA 2026
A broad slate of Korean pharma and biotech firms used Bio USA 2026 to chase partnering deals, from organoid platforms to stem-cell and CDMO work.
- Korean Biotech at BIO USA 2026: Licensing Deals Over Product Launches
Korean drugmakers used BIO USA 2026 to court partners rather than launch products, with Curacle's 1.6 trillion won deal setting the benchmark.
- Korea's First-Half Exports Hit Records From Chips to Strawberries
Korea posted record first-half 2026 exports across ICT, biopharmaceuticals, farm fruit and Ulsan's silver trade, with AI demand and food diversification leading
- Korean Biotech at BIO 2026: Kangstem Courts a Partner as Data Nears
Korean drug developers pushed partnering deals at BIO USA 2026, with Kangstem Biotech awaiting late-July Phase 2 data and G2G Bio fresh off its KOSDAQ debut.
- Korean Biotech Takes Home-Built Strengths to BIO USA 2026
At BIO USA 2026, Korean biotech leaders from MediSapiens, G2G Bio and Lotte Biologics pitched global partners on capabilities built at home.
- Korea's Biopharma Makes Its Case at BIO USA 2026
Korean drugmakers from SK Biopharm to DXVX used BIO USA 2026 to court partners across CDMO, clinical analytics and licensing pipelines.
- Korean Biotech's Four-Day Push at BIO USA 2026
Korean pharma and biotech firms used a packed four-day BIO USA 2026 schedule to court partners, from Kanaph Therapeutics to SK Biopharm and DXVX.
